Norbert Bischofberger - Gilead Sciences Insider

Gilead Sciences Inc -- USA Stock  

USD 80.01  1.2  1.48%

Chief Scientific Officer and Executive VP of RandD

Dr. Norbert W. Bischofberger, Ph.D., is Executive Vice President of Research and Development, Chief Scientific Officer of Gilead Sciences Inc
Age: 60  EVP Since 2007  Ph.D    
650 574-3000  www.gilead.com
Bischofberger joined Gilead in 1990 and has served as Executive Vice President, Research and Development since 2000 and Chief Scientific Officer since 2007. Prior to joining Gilead, Dr. Bischofberger was a Senior Scientist in Genentech, Inc.?s DNA Synthesis group from 1986 to 1990. He received his Ph.D. in Organic Chemistry at the Eidgenossische Technische Hochschule in Zurich, Switzerland and performed postdoctoral research in steroid chemistry at Syntex. He also performed additional research in organic chemistry and applied enzymology in Professor George Whiteside?s lab at Harvard University in Cambridge, Massachusetts.

Norbert Bischofberger Latest Insider Activity

Norbert Bischofberger over two months ago via Macroaxis 
Gilead Sciences exotic insider transaction detected
Norbert Bischofberger over six months ago via Macroaxis 
Sale by Norbert Bischofberger of 11679 shares of Gilead Sciences
Norbert Bischofberger over six months ago via Macroaxis 
Sale by Norbert Bischofberger of 6427 shares of Gilead Sciences

Management Efficiency

The company has return on total asset (ROA) of 19.03 % which means that it generated profit of $19.03 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 62.19 % meaning that it created $62.19 on every $100 dollars invested by stockholders.
The company currently holds 26.3 B in liabilities with Debt to Equity (D/E) ratio of 113.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Gilead Sciences Inc has Current Ratio of 3.3 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 8 records

EVP Since

Hubert AllenAbbott Laboratories
2013
Brian BlaserAbbott Laboratories
2012
Giovanni MagniBio Rad Laboratories Inc
2014
Stuart ArbuckleVertex Pharmaceuticals Incorpor
2012
Susan HallEndo International plc
2014
Richard AshleyAbbott Laboratories
2004
Thomas FreymanAbbott Laboratories
2015
John CapekAbbott Laboratories
2015

Entity Summary

Gilead Sciences Inc., a researchbased biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the AsiaPacific. Gilead Sciences Inc (GILD) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 8,000 people. Gilead Sciences is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Alpha Finder Now
   

Alpha Finder

Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Hide  View All  Next  Launch Alpha Finder
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Gilead Sciences Inc to your portfolio

Top Management

Gilead Sciences Inc Leadership Team
Kathleen Watson, President
Nicholas Moore, Director
James Meyers, President
Kelly Kramer, Director
Andrew Cheng, President
John Martin, Chairman, MBA
Robin Washington, CFO, MBA
Norbert Bischofberger, EVP, Ph.D
Per WoldOlsen, Director
Gayle Wilson, Director
Taiyin Yang, President, Ph.D
Brett Pletcher, EVP
William Lee, President
John Madigan, Director
Martin Silverstein, President, MBA
Kevin Lofton, Director
Kevin Young, COO
Etienne Davignon, Director
Richard Whitley, Director
Paul Carter, President
Gregg Alton, EVP
Carla Hills, Director, MBA
John Cogan, Director
John Milligan, COO, Ph.D

Stock Performance

Gilead Sciences Performance Indicators